The phar­ma in­dus­try's rep hits ab­solute. rock. bot­tom.

Af­ter two years of be­ing pil­lo­ried by the pres­i­dent and law­mak­ers for drug pric­ing, spark­ing head­lines about huge judg­ments levied for trig­ger­ing the opi­oid epi­dem­ic (J&J) and hid­ing ma­nip­u­lat­ed da­ta dur­ing an FDA re­view (No­var­tis), it may come as no sur­prise to hear that the in­dus­try’s rep­u­ta­tion has suf­fered some.

But it’s worse than that.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.